WEB-IT Study:

The WEB™ Intrasaccular Therapy Study
WEB™ Intrasaccular Embolization

"Five year follow-up data from the WEB-IT study demonstrated that the WEB™ device was safe and effective when used in the treatment of WNBAs. Aneurysm occlusion rates achieved at 1 year follow-up were durable, with rates of progressive thrombosis far exceeding rates of recurrence over time."

Patients

150

Countries

US, Turkey, Hungary, Germany, Canada, Denmark

Clinical Centers

27

Design

Single arm prospective

Scope

Patients 18-75 y.o., with wide neck bifurcation intracranial aneurysms ruptured or unruptured, H&H<3, treatable with WEB only

Purpose

Assessment of safety, efficacy and technical success of WEB up to 5 years.

1 year: Evaluate safety and effectiveness of WEB in support of an application for Food and Drug Administration approval in the USA.

Endpoints

Effectiveness:

  • Complete aneurysm occlusion without retreatment, recurrent SAH, without significant Parent Artery Stenosis (>50% stenosis) at 12 months (assessed by Corelab)

Safety:

  • Proportion of subjects with death of any nonaccidental cause or any major stroke within the first 30 days after treatment, or major ipsilateral stroke or death due to neurologic cause from day 31 to the 1 year after treatment

LINK TO STUDY PAGE Clinical Trials.gov ID NCT02191618

Please refer to Instruction for Use (IFU) in the specific market/country that you are looking into:

Explore more studies

CLARYS Study: CLinical Assessment of WEB™ Device in Ruptured aneurYSms

WEB™ Intrasaccular Embolization

French Observatory Study: WEB™ French Observatory of the WEB Aneurysm Embolization System

WEB™ Intrasaccular Embolization

CLEVER Study: CLinical EValuation of WEB™ 0.017 Device in Intracranial AneuRysms

WEB™ Intrasaccular Embolization

Request more information

The information you provide through this form is necessary to respond to your request and may be shared with the relevant Terumo Neuro group entity or entities responsible for handling it. For more information on how we process your personal data and on your rights, please refer to our privacy policy.